Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasculitis24.05.02.001; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.000443%
Visual acuity reduced17.17.01.011; 06.02.03.0010.000316%
Visual impairment06.02.06.0080.001518%Not Available
Vitreous floaters06.09.01.0050.000126%
Vomiting07.01.07.003--
Weight decreased13.15.01.0050.000316%
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000126%
Oesophagitis ulcerative07.04.05.003--Not Available
Excoriation23.03.11.003; 12.01.06.007--Not Available
Contusion12.01.06.001; 24.07.06.001; 23.03.11.002; 15.03.01.0080.000253%
Rhinalgia22.02.05.0320.000126%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Nasal discomfort22.02.05.020--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Anterior chamber cell06.04.10.0010.000126%Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Muscle mass15.05.03.018--Not Available
Staphylococcal infection11.02.05.0020.000506%Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.0100.000253%Not Available
Bacterial infection11.02.01.0050.000126%Not Available
Embolism24.01.01.009--
Inflammation08.01.05.0070.000379%Not Available
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.038--
Extradural abscess17.06.07.003; 11.01.03.0060.000126%Not Available
Psychotic disorder19.03.01.0020.000126%
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages